Nuvalent Appoints Christy Oliger to Board of Directors

Core Insights - Nuvalent, Inc. has appointed Christy Oliger to its Board of Directors, enhancing its leadership as it transitions from a development-stage company to potential commercialization [1][2] - Oliger brings over 30 years of experience in the pharmaceutical and biotechnology industry, including her recent role as Senior Vice President at Genentech, where she oversaw U.S. commercial activities in oncology [2] - The company is preparing for a potential first approval of its novel kinase inhibitors in 2026, reflecting its commitment to delivering targeted therapies for cancer patients [2][3] Company Overview - Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing precisely targeted therapies for cancer, specifically targeting clinically proven kinase targets [3] - The company utilizes expertise in chemistry and structure-based drug design to create innovative small molecules aimed at overcoming resistance and minimizing adverse events [3] - Nuvalent's pipeline includes investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, along with multiple discovery-stage research programs [3]